학술논문
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
Document Type
Article
Author
Gaudinski, Martin R; Houser, Katherine V; Doria-Rose, Nicole A; Chen, Grace L; Rothwell, Ro Shauna S; Berkowitz, Nina; Costner, Pamela; Holman, LaSonji A; Gordon, Ingelise J; Hendel, Cynthia S; Kaltovich, Florence; Conan-Cibotti, Michelle; Gomez Lorenzo, Margarita; Carter, Cristina; Sitar, Sandra; Carlton, Kevin; Gall, Jason; Laurencot, Carolyn; Lin, Bob C; Bailer, Robert T; McDermott, Adrian B; Ko, Sung-Youl; Pegu, Amarendra; Kwon, Young D; Kwong, Peter D; Namboodiri, Aryan M; Pandey, Janardan P; Schwartz, Richard; Arnold, Frank; Hu, Zonghui; Zhang, Lily; Huang, Yunda; Koup, Richard A; Capparelli, Edmund V; Graham, Barney S; Mascola, John R; Ledgerwood, Julie E; Mendoza, Floreliz; Novik, Laura; Zephir, Kathy; Whalen, William; Larkin, Brenda; Saunders, Jamie; Cunningham, Jennifer; Levinson, Carol; Wang, Xiaolin; Plummer, Sarah; Victorino, Milalynn; Ola, Abidemi; Boyd, Catina; Jayasinghe, Nilusha; Apte, Preeti; Cartagena, Cora Trelles; Hicks, Renunda; Williams, Pernell; Vasilenko, Olga; Yamshchikov, Galina; Florez, Maria Burgos; Pittman, Iris; Gama, Lucio; Casazza, Joseph; DeCederfelt, Hope; Cheng, KC; Stein, Judy
Source
The Lancet HIV; October 2019, Vol. 6 Issue: 10 pe667-e679, 13p
Subject
Language
ISSN
24054704; 23523018
Abstract
Human monoclonal antibodies that potently and broadly neutralise HIV-1 are under development to prevent and treat HIV-1 infection. In this phase 1 clinical trial we aimed to determine the safety, tolerability, and pharmacokinetic profile of the broadly neutralising monoclonal antibody VRC07-523LS, an engineered variant of VRC01 that targets the CD4 binding site of the HIV-1 envelope protein.